Recap: Immunogen Q4 Earnings

Shares of Immunogen IMGN moved higher by 2.9% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 433.33% year over year to $0.16, which beat the estimate of ($0.08).

Revenue of $85,798,000 up by 91.24% year over year, which beat the estimate of $40,830,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $65,000,000 and $75,000,000.

Details Of The Call

Date: Feb 12, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kk8uk2b5

Technicals

Company's 52-week high was at $8.33

Company's 52-week low was at $1.95

Price action over last quarter: Up 33.82%

Company Profile

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.